Creative Medical Technology Holdings, Inc. ((CELZ)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Creative Medical Technology Holdings, Inc. (CELZ) is conducting a study titled A Double-blinded, Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Effectiveness of CELZ-201-DDT Administered by Intramuscular Injection for the Treatment of Chronic Lower Back Pain in Patients With Degenerative Disc Disease. The study aims to assess the safety, tolerability, and efficacy of CELZ-201-DDT in treating chronic lower back pain associated with degenerative disc disease.
The intervention being tested is CELZ-201-DDT, a drug administered via intramuscular injection into the lumbar paraspinal musculature. The purpose is to alleviate chronic lower back pain in patients with degenerative disc disease.
The study is designed as a double-blinded, randomized, placebo-controlled trial with a parallel intervention model. The primary purpose is treatment, and both participants and investigators are masked to the treatment allocation.
The study began on September 17, 2023, and is currently recruiting participants. The primary completion date and estimated study completion date are not specified, but the last update was submitted on August 22, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
The study’s progress could influence CELZ’s stock performance and investor sentiment, especially if the results demonstrate significant efficacy and safety. This could position CELZ favorably against competitors in the chronic pain treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.